Schizophrenia/Psychosis

Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.

Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.

Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.

Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.

Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.

Xanomeline-trospium targets muscarinic receptors for schizophrenia relief with fewer side effects, and early data suggest cognitive gains.

Study finds most teens with first-episode psychosis stop antipsychotics within a year, boosting ER use; outpatient care and injectables may help.

Cobenfy revived shelved muscarinic therapy for schizophrenia, easing side effects while boosting negative and cognitive symptoms across trials.

Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.

Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.

Can hormones flag suicide risk in schizophrenia? Review links cortisol, thyroid and testosterone shifts—and clozapine/lithium pathways—to risk.

Explore how TMS might be useful in treating schizophrenia, and how researchers are working to localize target areas.

RADIANT phase 2 shows once-daily remlifanserin eases Alzheimer’s psychosis symptoms with placebo-like safety, advancing pivotal trials.

Causal lesion and stimulation studies map psychosis to hippocampus–thalamus circuits, pointing to a reproducible TMS target for schizophrenia symptoms.

Adolescent synaptic pruning may fuel schizophrenia; researchers explore how restoring plasticity could ease fixed delusions.

Primate brain tissue studies track pruning, myelination, and dopamine across development, revealing adolescence-linked neural dynamics that may explain schizophrenia risk.

Discover how integrated psychotherapy—CBTp, family support, and relapse plans—boosts schizophrenia recovery alongside antipsychotics.

A case report and review of 13 similar cases suggest that late-onset clozapine neutropenia may sometimes reflect neutrophil margination rather than marrow suppression, with corticosteroids, granulocyte colony-stimulating factor, or lithium as possible, carefully monitored paths to continuing treatment.

Real-world data highlights Lybalvi’s impact on acute care use in high-risk patients and Aristada’s long-acting dosing for steadier schizophrenia treatment.

Medicare claims show pimavanserin in Parkinson psychosis nursing homes links to fewer falls and recurrent falls than quetiapine or other antipsychotics.

How online scams and AI deepfakes prey on people with schizophrenia, triggering relapse—plus practical clinician screening and safety planning tips.

Real‑world inpatient use of xanomeline/trospium shows rapid awakening from negative symptoms in schizophrenia, with response predictors and striking case insights.

New case suggests muscarinic therapy xanomeline/trospium calms treatment‑resistant bipolar I mania with psychosis, hinting at nondopamine options.

Learn how experts distinguish agitation from psychosis in Alzheimer disease, weigh new FDA options, and apply evidence for off-label care.

Three posters presented at APA 2026 detail real-world treatment patterns, pooled long-term cardiometabolic safety, and urinary adverse event rates with xanomeline and trospium chloride.